Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cardeaspharma.com

Stage

Series B - II | Dead

Total Raised

$49.02M

Last Raised

$3.5M

About Cardeas Pharma

Cardeas is a privately held biopharmaceutical company dedicated to the development and commercialization of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining formulations of proven antibiotics with drug delivery technology, Cardeas seeks to address significant unmet medical needs in the critical-care setting.

Cardeas Pharma Headquarters Location

2025 First Avenue Suite 1200

Seattle, Washington, 98121,

United States

206-973-1026

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cardeas Pharma Patents

Cardeas Pharma has filed 12 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/7/2016

9/10/2019

Aminoglycoside antibiotics, Dosage forms, Drug delivery devices, Antibiotics, Bacterial diseases

Grant

Application Date

11/7/2016

Grant Date

9/10/2019

Title

Related Topics

Aminoglycoside antibiotics, Dosage forms, Drug delivery devices, Antibiotics, Bacterial diseases

Status

Grant

Latest Cardeas Pharma News

Cardeas Pharma Corp Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

Jan 9, 2017

Cardeas Pharma Corp Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 22:48 EST 8 Jan 2017 | BioPortfolio Reports Home » Topics » Top 50 Biopharma Products 2011 » Latest News » Cardeas Pharma Corp Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Cardeas Pharma Corp CP is a biopharmaceutical company that develops and commercializes inhaled antibiotics to treat serious, hospitalacquired respiratory infections with antibioticresistant organisms. The company offers antibiotic formulation of drugs such as Amikacin and Fosfomycin against Gramnegative bacilli including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenemresistant enterobacteriaceae. The company provides drugs against grampositive pathogens including methicillinresistant Staphylococcus aureus. Its eFlow InLine nebulizer system uses eFlow technology to enable efficient aerosol delivery of medication to intubated patients on a mechanical ventilator. CP is headquartered in Seattle, Washington, the US. Cardeas Pharma Corp Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

  • Where is Cardeas Pharma's headquarters?

    Cardeas Pharma's headquarters is located at 2025 First Avenue, Seattle.

  • What is Cardeas Pharma's latest funding round?

    Cardeas Pharma's latest funding round is Series B - II.

  • How much did Cardeas Pharma raise?

    Cardeas Pharma raised a total of $49.02M.

  • Who are the investors of Cardeas Pharma?

    Investors of Cardeas Pharma include Novo Holdings, Devon Park Bioventures, Avalon Ventures, Delphi Ventures, H.I.G. BioHealth Partners and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.